Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TINCRBEL study of rivaroxaban in short bowel syndrome patients on long-term parenteral nutrition
2018-001845-15Phase 4Active
- Sponsor
- Amsterdam UMC
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in catheter-related thrombosis (CRT) and Phlebothrombosis, sponsored by Amsterdam UMC. Primary endpoints: Clinical outcomes after at least one year and Variability in laboratory concentrations. Started Jun 2018; status: active.
02
Drugs
rivaroxaban
03
Conditions
catheter-related thrombosis (CRT)Phlebothrombosis
Beyond the preview
Go deeper on 2018-001845-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001845-15.